Core Insights - Kiniksa Pharmaceuticals reported strong sales growth for ARCALYST, achieving 417.0millioninnetproductrevenueforthefullyear2024,a79560 million and 580millionin2025[2][10]−KiniksaplanstodiscontinuethedevelopmentofabiprubartinSjo¨gren′sDiseaseandfocusoncardiovascularindications[2][7]FinancialPerformance−TotalrevenueforQ42024was122.5 million, compared to 83.4millioninQ42023[10][25]−Fullyear2024totalrevenuewas423.2 million, up from 270.3millionin2023[10][25]−ThenetlossforQ42024was8.9 million, compared to a net income of 25.2millioninQ42023[10][25]−Forthefullyear2024,thenetlosswas43.2 million, compared to a net income of $14.1 million in 2023 [10][25] Product Development - Kiniksa is advancing KPL-387 for recurrent pericarditis, with a Phase 2/3 clinical trial expected to start in mid-2025 [2][8][10] - KPL-387 aims to provide a single monthly subcutaneous injection option for patients [2][7] - KPL-1161 is also being developed with a target profile of quarterly subcutaneous dosing [7][9] Market Position - Since the launch of ARCALYST, over 2,850 prescribers have written prescriptions for recurrent pericarditis [7] - As of Q4 2024, approximately 13% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment [7]
Kiniksa(KNSA) Newsfilter·2025-02-25 12:30